Skip to content

Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors-Renewal

Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors-Renewal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03186508
Enrollment
149
Registered
2017-06-14
Start date
2018-02-28
Completion date
2023-09-19
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Sleep

Keywords

obesity prevention, sleep, behavioral intervention

Brief summary

Enhancing children's sleep may be a novel approach for prevention of obesity and cardiovascular (CV) disturbance. Observational studies with children demonstrate that short sleep increases risk of obesity and other CV risk factors. Randomized controlled trials with children 8-11 years old demonstrate that enhancing sleep duration leads to positive changes in eating and activity behaviors and weight status, particularly for children who enhance their sleep the most. Enhancing sleep may be particularly important for racial minority children and those from lower socioeconomic backgrounds given their increased risk for short sleep, obesity and CV risk factors. In this study two active obesity preventive interventions will be evaluated: a) enhancing sleep alone (Optimize Sleep \[OS\]), and b) enhancing sleep along with eating and activity behaviors that have demonstrated efficacy for obesity prevention and are implicated in self-regulatory pathways related to sleep (i.e., energy dense snack foods and beverages, TV viewing, and physical activity) (OS-Plus). Two hundred four children 6-11 years old who are primarily African American/black, primarily from low socioeconomic backgrounds, and who sleep \< 9.5 hours/night into a 12-month study will be enrolled. Children will be randomly assigned to either OS or OS-Plus. Over the 6-month treatment phase, all children will attend an 8-session treatment; monthly phone contacts will occur during maintenance (6-12 months). Primary aim is to determine the efficacy of OS-Plus relative to OS on change in body mass index z-score (BMIz) at end of treatment. Secondary aims will assess efficacy of OS-Plus relative to OS on additional cardiometabolic risk factors, eating and activity behaviors. Exploratory aims will assess maintenance of effects at 12 months.

Interventions

BEHAVIORALOptimize Sleep (OS)

All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.

BEHAVIORALOptimize Sleep-Plus (OS-Plus)

All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Temple University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

1. Caregiver-reported child age of 6-11 years 2. \< 9.5 Hours time-in-bed for sleep most days/week 3. BMI for age and gender \> 25th percentile (but no greater than 100% overweight) 4. Understanding of and ability to complete protocol 5. Self-reported caregiver age of 18 years and primary caregiver at bedtimes/wake times 6. Likes food used in the eating regulation paradigms 7. Willingness to be randomized to either treatment condition.

Exclusion criteria

1. Diagnosable sleep disorder 2. Medication use or diagnosis of medical or psychiatric condition that may impact sleep/weight status 3. Current or planned treatment for weight control 4. Allergies or dietary restrictions that would prevent consumption of foods used in the study

Design outcomes

Primary

MeasureTime frameDescription
Change in BMIzChange from baseline BMIz at 6 monthschange in body mass index z-score (accounting for child age and sex)

Secondary

MeasureTime frameDescription
Change in Waist CircumferenceChange from baseline waist circumference at 6 monthsChange in measured waist circumference
Change in Insulin ResistanceChange from baseline HOMA-IR at 6 monthsChange in the homeostatic model assessment of insulin resistance (HOMA-IR)
Change in Blood Glucose LevelsChange from baseline blood glucose levels at 6 months2-hour blood glucose levels measured within the context of an oral glucose tolerance test
Change in Non-HDL cholesterol (non-HDL-C)Change from baseline in Non-HDL-C at 6 monthsTotal cholesterol (TC) minus HDL-C, includes LDL-C, VLDL-C, and atherogenic apo-B containing lipoproteins
Change in Insulin Sensitivity Index (ISI)Change from baseline ISI at 6 monthsInsulin Sensitivity Index measured within the context of an oral glucose tolerance test
Change in Body CompositionChange from baseline percent body fat at 6 monthschange in body composition (% body fat) will be estimated by air displacement plethysmography (BOD POD®; Life Measurement Instruments, Concord, CA)
Change in Caloric IntakeChange from baseline in caloric intake at 6 months24-hr dietary recalls on two days used to estimate caloric intake
Change in Food ReinforcementChange from baseline in food reinforcement at 6 monthsMeasured using a validated computer activity (Behavioral Choice Task), which assesses motivation for a food reward
Change in Eating in the Absence of Hunger (EAH)Change from baseline in EAH at 6 monthsFood consumed within the context of the eating in the absence of hunger paradigm
Change in Percent Time spent in Moderate to Vigorous Physical Activity (MVPA)Change from baseline in MVPA at 6 monthsWaist-worn accelerometer
Change in Sleep PeriodChange from baseline in the sleep period at 6 monthsWrist-worn actigraphy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026